A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 microg o.d.) in Patients With Persistent Asthma
Latest Information Update: 10 Jan 2022
At a glance
- Drugs Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.